Exosomes for Hairloss Treatment

Launched by GUANGZHOU BIO-GENE TECHNOLOGY CO., LTD · Apr 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the use of exosomes, which are tiny particles derived from stem cells, as a potential treatment for hair loss, specifically alopecia. Alopecia can be caused by genetic factors, stress, and other health issues, leading to both physical and emotional challenges for those affected. The trial aims to see if exosome therapy can help improve hair growth and assess its safety. It is designed for adults aged 18 to 75, regardless of gender, who have specific types of hair loss and meet certain health criteria.

Participants will be randomly assigned to receive different doses of the exosome treatment and will not know which dose they are receiving, ensuring that the results are unbiased. Those eligible should not have any other significant health issues that could affect hair growth or have recently used certain medications or treatments for hair loss. It's important for potential participants to be open to following specific guidelines during the study, like avoiding other hair loss treatments and using a neutral shampoo. This trial is currently not recruiting, but it represents an exciting possibility for those looking for new solutions to hair loss.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subjects are able to read documents and can sign informed consent.
• • 2. 18\~75 years old (including the threshold), gender is not limited.
• 3. The subject's "hair loss grade" meets the following criteria:
• • 1) BASP grade: Basic type (M2 to M3, or C2 to C3, or U1 to U3) or special type (V1 to V3, or F1 to F3); 2) For female: Ludwig Grade I to II. Or for male: Hamilton-Norwood Grade III to IV; 3) Hair density by phototrichogram: ≤ 190 hair/cm² ; 4. Hair dryness ≥ 5%; 5. Until withdrawal/completion of the study, subjects agree not to undergo any topical treatment for hair loss and agree to use a neutral shampoo.
• Exclusion Criteria:
• • 1. People with patchy or diffuse baldness, syphilitic alopecia, scarring alopecia, malnutrition, chemotherapy/radiotherapy-induced hair loss.
• • 2. Those with a combination of diseases that have an impact on hair growth.
• • 3. Use of medications, medicated shampoos, or hair care products that may interfere with efficacy evaluation within 3 months prior to screening (oral administration of therapeutic agents for androgenetic alopecia must be discontinued for at least 6 months).
• • 4. Have received scalp radiation and/or laser or surgical therapy within 3 months prior to screening.
• • 5. Participated or are participating in a interventional clinical trial within 3 months.
• • 6. Persons with a history of hereditary alopecia areata.
• • 7. Women who are pregnant or breastfeeding, or male/female subjects whose own/partner's pregnancy is planned within 6 months.
• • 8. Have undergone hair transplantation in the previous 24 months.
• • 9. Individuals testing positive for active infectious diseases or carriers of communicable pathogens.
• • 10. Those with keloid, keloid-prone or hyperplastic scarring.
• • 11. Those who, in the opinion of the investigator, are otherwise unfit to participate in this clinical study.